Valvular & structural heart disease
A comparison of antiplatelet and oral anticoagulation strategies to prevent cerebral microembolism after transcatheter aortic valve implantation: the AUREA trial
Authors' conclusion
In patients without an indication for OAC, an OAC strategy for 3 months post-TAVI did not show any benefit over an antiplatelet strategy in preventing cerebral microembolism. Patients treated with DAPT showed a lower mean volume of brain damage on DW-MRI during the 90 days following TAVI compared to those treated with acenocoumarol.
Study context
- Population
- Patients with aortic stenosis and no indication for oral anticoagulation (OAC) undergoing transcatheter aortic valve implantation (TAVI)patients included in the study
- Participants
- 123 patients
- Comparison
- Dual antiplatelet therapy (DAPT) versus OAC in preventing cerebral microembolism during the first 3 months post-TAVI
- Primary endpoint
- Proportion of patients with new cerebral emboli on diffusion-weighted magnetic resonance imaging (DW-MRI)
- Follow-up
- 6 and 90 days post-TAVI
Primary result
As reported in the abstract
6 days
90 days
Further findings
| Outcome | OAC | DAPT |
|---|---|---|
| Mean total emboli volume · 6 days and cumulatively at 6+90 days | ||
| 6 days | 303.4 mm³ | 265.9 mm³ |
| 6+90 days | 331.10 mm³ | 266.45 mm³ |
- Mean total emboli volume: 6 days: p=0.019
- Mean total emboli volume: 6+90 days: p=0.008
Mean total emboli volume · 6 days and cumulatively at 6+90 days
- Lower mean total emboli volume with DAPT
New cerebral emboli on baseline MRI prior to TAVI
- Patients with new cerebral emboli on baseline MRI
- 3.3%
Original publication
A comparison of antiplatelet and oral anticoagulation strategies to prevent cerebral microembolism after transcatheter aortic valve implantation: the AUREA trial. EuroIntervention. Published 7 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →